The innovative drug concept collectively declined. Lianhuan Pharmaceutical and Onlikang both fell to a standstill. Previously, Minovar fell to a standstill, Tianjin Pharmaceutical was close to a standstill, and Shu Taishen and Hualan shares fell by more than 11%, followed by Frontier Biology, Kangzhi Pharmaceutical, and Shuanglu Pharmaceutical.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.